CA Patent

CA3056179A1 — Nucleic acid products for interfering with or inhibiting target gene expression and compositions and uses thereof

Assigned to Silence Therapeutics GmbH · Expires 2018-10-11 · 8y expired

What this patent protects

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.

USPTO Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.

Drugs covered by this patent

Patent Metadata

Patent number
CA3056179A1
Jurisdiction
CA
Classification
—
Expires
2018-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Silence Therapeutics GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.